Employers are enthusiastic that effective new drugs to address obesity are now available but are distraught by their exceptionally high-cost impact. The GLP-1 class of obesity medicines can lead to 15% to 20% body weight loss, which can dramatically decrease health risks. However, Wegovy (semaglutide) and Mounjaro (tirzepatide) retail for over $16,000 and cost employers close to $10,000 annually even after discounts and rebates. Facing rising costs, employers are re-examining their strategies to support employees to address obesity and cardiometabolic syndrome.
Providing support to employees in this area can be challenging, as obesity is influenced by many factors. Obese individuals rarely lose more than 6% of their weight without medical or surgical intervention. Bariatric surgery is expensive and has been performed on less than 1% of those who are obese. Semaglutide and tirzepatide are highly effective but are currently only covered by 38% of employers. Three quarters (74%) of employers that provide GLP-1 coverage have, or are considering, access restrictions such as raised BMI thresholds, coverage or treatment limits or requiring step therapy with behavioral modification programs.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
